Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | October 06, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date October 06, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,108,287 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 50,000 · Balance 6,108,287 F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 7, 2026 22:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 50,000 | $4.84 | $242,000.00 |
DisclosureSEC source: 0001601830-26-000120 · wk-form4_1791410921.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,108,287 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $3.34 | $100,200.00 |
DisclosureSEC source: 0001601830-26-000103 · wk-form4_1788386512.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,158,287 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 21:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $3.25 | $97,500.00 |
DisclosureSEC source: 0001856094-26-000014 · wk-form4_1786050562.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,188,287 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 22:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 40,000 | $3.96 | $158,500.00 |
DisclosureSEC source: 0001856094-26-000011 · wk-form4_1783634656.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,218,287 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.95 to $4.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 88,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000088 · wk-form4_1782160357.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,258,287 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 21:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $3.68 | $110,400.00 |
DisclosureSEC source: 0001856094-26-000008 · wk-form4_1780607089.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,169,863 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:44 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $3.52 | $105,600.00 |
DisclosureSEC source: 0001856094-26-000005 · wk-form4_1778186681.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,199,863 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $3.10 | $93,000.00 |
DisclosureSEC source: 0001856094-26-000003 · wk-form4_1775681895.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,229,863 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 170,000 | $3.46 | $588,200.00 |
DisclosureSEC source: 0001601830-26-000045 · wk-form4_1772660322.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,259,863 Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 22:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 220,000 | $4.20 | $924,000.00 |
DisclosureSEC source: 0001601830-26-000007 · wk-form4_1770418411.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,429,863 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 220,000 | $4.36 | $959,200.00 |
DisclosureSEC source: 0001856094-26-000002 · wk-form4_1767909697.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,649,863 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:51 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 220,000 | $4.37 | $961,400.00 |
DisclosureSEC source: 0001856094-25-000006 · wk-form4_1764885089.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,869,863 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 44,031 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001601830-25-000112 · wk-form4_1750713817.xml · derivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,031 Underlying: Class A Common Stock · 44,031 shares Expires 2035-06-18 F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 22,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000112 · wk-form4_1750713817.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,089,863 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:02 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000004 · wk-form4_1736204544.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,067,847 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| November 12, 2024 Filed Nov 15, 2024 00:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $7.64 | $87,457.37 |
DisclosureSEC source: 0001601830-24-000205 · wk-form4_1731629981.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,066,113 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.48 to $8.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 29, 2024 Filed Oct 31, 2024 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $6.72 | $76,926.13 |
DisclosureSEC source: 0001601830-24-000186 · wk-form4_1730412083.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,077,560 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.67 to $6.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 21:27 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $6.67 | $76,326.31 |
DisclosureSEC source: 0001601830-24-000179 · wk-form4_1729200457.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,089,007 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.50 to $6.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $6.22 | $71,149.97 |
DisclosureSEC source: 0001601830-24-000166 · wk-form4_1727989110.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,098,428 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.09 to $6.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000174 · wk-form4_1728081022.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,100,454 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 21:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $6.84 | $78,332.97 |
DisclosureSEC source: 0001601830-24-000160 · wk-form4_1726782500.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,109,875 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.74 to $7.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $6.27 | $71,717.74 |
DisclosureSEC source: 0001601830-24-000154 · wk-form4_1725571513.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,121,322 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $5.96 to $6.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 22:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $7.12 | $81,532.40 |
DisclosureSEC source: 0001601830-24-000129 · wk-form4_1724366895.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,132,769 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.99 to $7.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $6.82 | $78,083.42 |
DisclosureSEC source: 0001601830-24-000119 · wk-form4_1723152181.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,144,216 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.64 to $6.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 22:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $8.48 | $97,040.80 |
DisclosureSEC source: 0001601830-24-000104 · wk-form4_1721945720.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,155,663 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.94 to $8.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:51 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $7.32 | $83,734.81 |
DisclosureSEC source: 0001601830-24-000100 · wk-form4_1720731088.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,167,110 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.17 to $7.435. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000096 · wk-form4_1720039166.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,178,557 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 23:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $9.51 | $108,806.02 |
DisclosureSEC source: 0001601830-24-000094 · wk-form4_1719529999.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,177,116 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.325 to $9.82. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:36 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $8.45 | $96,762.64 |
DisclosureSEC source: 0001601830-24-000082 · wk-form4_1718314568.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,188,563 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.285 to $8.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 26,193 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001601830-24-000071 · wk-form4_1717625511.xml · derivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,193 Underlying: Class A Common Stock · 26,193 shares Expires 2034-06-03 F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 13,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000071 · wk-form4_1717625511.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,200,010 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. Read SEC document |
| May 28, 2024 Filed May 30, 2024 22:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $9.17 | $104,942.66 |
DisclosureSEC source: 0001601830-24-000067 · wk-form4_1717108876.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,186,913 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.88 to $9.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,054 | $10.12 | $202,934.45 |
DisclosureSEC source: 0001601830-24-000055 · wk-form4_1715891720.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,198,360 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.74 to $10.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 30, 2024 Filed May 2, 2024 21:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $7.95 | $90,963.59 |
DisclosureSEC source: 0001601830-24-000046 · wk-form4_1714686087.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,218,414 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.81 to $8.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 21:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $7.66 | $87,725.23 |
DisclosureSEC source: 0001601830-24-000037 · wk-form4_1713474744.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229,861 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.54 to $7.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 21:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $8.82 | $100,941.94 |
DisclosureSEC source: 0001601830-24-000027 · wk-form4_1712180546.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,241,308 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.71 to $8.98 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,054 | $10.79 | $216,422.77 |
DisclosureSEC source: 0001601830-24-000024 · wk-form4_1711057070.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,252,755 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.55 to $11.14 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,054 | $12.06 | $241,805.12 |
DisclosureSEC source: 0001601830-24-000021 · wk-form4_1709855609.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,272,809 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.64 to $12.45 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 22:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 309 | $13.04 | $4,030.35 |
DisclosureSEC source: 0001209191-24-003708 · doc4.xml · nonDerivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,292,863 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.98 to $13.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 22:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 19,745 | $12.31 | $243,094.52 |
DisclosureSEC source: 0001209191-24-003708 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,293,172 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.97 to $12.96 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 23:54 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $9.30 | $106,489.15 |
DisclosureSEC source: 0001209191-24-003000 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,312,917 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.92 to $9.46 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,054 | $10.58 | $212,083.08 |
DisclosureSEC source: 0001209191-24-002250 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,324,364 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.41 to $10.78 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 13,751 | $13.81 | $189,924.69 |
DisclosureSEC source: 0001209191-24-001484 · doc4.xml · nonDerivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,344,418 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.50 to $14.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 6,303 | $13.21 | $83,277.76 |
DisclosureSEC source: 0001209191-24-001484 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,358,169 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.5 to $13.495 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 22:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,054 | $10.63 | $213,143.94 |
DisclosureSEC source: 0001209191-23-059947 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,364,472 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.38 to $10.89 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 23:51 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $7.40 | $84,692.92 |
DisclosureSEC source: 0001209191-23-058701 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,384,526 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.26 to $7.51 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 28, 2023 Filed Nov 30, 2023 22:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 11,447 | $6.72 | $76,918.12 |
DisclosureSEC source: 0001209191-23-056998 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,395,973 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.35 to $7.03 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:55 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $6.32 | $56,150.53 |
DisclosureSEC source: 0001209191-23-055613 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,407,420 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.13 to $6.485 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 23:02 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $5.27 | $46,863.93 |
DisclosureSEC source: 0001209191-23-054225 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,416,305 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $5.21 to $5.35 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 21:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $6.58 | $58,482.85 |
DisclosureSEC source: 0001209191-23-053196 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,425,190 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.47 to $6.70 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.